Zuranolone shows promise as episodic treatment for depression | 化學工廠資訊網
2022年9月20日—NewdatasupportsthepotentialuseofBiogen'sandSageTherapeutics'zuranoloneasapotentialepisodictreatmentforpeoplewithmajor ...
Phase III data shows most major depressive disorder patients treated with zuranolone had minimal or mild depressive symptoms after a year.
New data supports the potential use of Biogen’s and Sage Therapeutics’ zuranolone as a potential episodic treatment for people with major depressive disorder (MDD). Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression.
In the ongoing open-label, longitudinal SHORELINE Study in MDD, the median time to the first repeat treatment course for those patients who responded to the initial 14-day treatment course was 135 days for the completed 30mg cohort (n = 489) and 249 days for the ongoing 50mg cohort (n = 146).
Additionally, an analysis of patients in the 30mg cohort with elevated anxiety (n = 569) and without elevated anxiety (n = 1...
Effect of Zuranolone vs Placebo in Postpartum Depression | 化學工廠資訊網
New Analyses Strengthen Efficacy | 化學工廠資訊網
Phase 3 SKYLARK Study of Zuranolone in Postpartum ... | 化學工廠資訊網
Sage Therapeutics and Biogen Announce that the Phase 3 ... | 化學工廠資訊網
Zuranolone - SAGE Therapeutics | 化學工廠資訊網
Zuranolone | 化學工廠資訊網
Zuranolone shows promise as episodic treatment for depression | 化學工廠資訊網
【新北市】瑞台生醫科技股份有限公司
新北市化工廠有哪些?本篇為大家整理位於新莊區化成路540號之1七樓之2的「瑞台生醫科技股份有限公司」相關資訊,用列表的方...